Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Routine Clinical Practice for Patients With Recurrent Ovarian Carcinoma: Results From the TROCADERO Study.

Freyer G, Ray-Coquard I, Fischer D, Martín AG, Kielhorn A, Chia V, Nanayakkara N, Taylor A.

Int J Gynecol Cancer. 2016 Feb;26(2):240-7. doi: 10.1097/IGC.0000000000000590.

PMID:
26745696
2.

Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.

Monk BJ, Coleman RL.

Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S63-7. doi: 10.1111/IGC.0b013e3181c104fa. Review.

PMID:
19955917
3.

Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.

Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N; Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DDL, deFazio A.

Gynecol Oncol. 2018 Aug;150(2):239-246. doi: 10.1016/j.ygyno.2018.05.020. Epub 2018 May 26.

PMID:
29807697
4.

Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance.

Chuang YT, Chang CL.

Taiwan J Obstet Gynecol. 2012 Sep;51(3):336-41. doi: 10.1016/j.tjog.2012.07.003. Review.

5.

Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.

Champer M, Huang Y, Hou JY, Tergas AI, Burke WM, Hillyer GC, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Gynecol Oncol. 2018 Jan;148(1):19-27. doi: 10.1016/j.ygyno.2017.11.008. Epub 2017 Nov 16.

PMID:
29153542
6.

Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).

Esposito F, Cecere SC, Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Scalone S, Rabaiotti E, Salutari V, Cormio G, Canuto EM, Greggi S, Savarese A, Marinaccio M, Scollo P, Santeufemia DA, Sacco C, Facchini G, Pignata S.

Oncology. 2014;86(5-6):351-8. doi: 10.1159/000358730. Epub 2014 Jun 12.

PMID:
24942520
7.

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).

Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F.

Gynecol Oncol. 2016 Mar;140(3):450-6. doi: 10.1016/j.ygyno.2015.12.025. Epub 2015 Dec 28.

PMID:
26731724
8.

Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.

Hoffman MA, Blessing JA, Morgan M.

Gynecol Oncol. 2000 Dec;79(3):463-5.

PMID:
11104620
9.

Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.

Bonaventura A, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML; Paragon Investigators.

Int J Gynecol Cancer. 2017 Jun;27(5):900-906. doi: 10.1097/IGC.0000000000000978.

PMID:
28498256
10.

Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.

Goto T, Takano M, Ohishi R, Iwasa N, Shimizu M, Hasegawa K, Nagao S, Fujiwara K.

J Obstet Gynaecol Res. 2010 Aug;36(4):764-8. doi: 10.1111/j.1447-0756.2010.01217.x.

PMID:
20666942
11.

A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

Hoffman MA, Blessing JA, Nuñez ER.

Gynecol Oncol. 2001 Jun;81(3):433-5.

PMID:
11371134
12.

A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.

Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord AA.

Gynecol Oncol. 2013 Jul;130(1):19-24. doi: 10.1016/j.ygyno.2013.04.049. Epub 2013 Apr 25.

PMID:
23623830
13.

Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.

Bookman MA, Tyczynski JE, Espirito JL, Wilson TW, Fernandes AW.

Gynecol Oncol. 2017 Jul;146(1):58-63. doi: 10.1016/j.ygyno.2017.04.011. Epub 2017 Apr 26.

PMID:
28454659
14.

Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.

Takekuma M, Kuji S, Tanaka A, Takahashi N, Abe M, Hirashima Y.

J Gynecol Oncol. 2015 Jul;26(3):185-92. doi: 10.3802/jgo.2015.26.3.185.

16.

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.

Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.

PMID:
27617661
17.

The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.

Safra T, Asna N, Veizman A, Shpigel S, Matcejevsky D, Inbar M, Grisaru D.

Anticancer Drugs. 2014 Mar;25(3):340-5. doi: 10.1097/CAD.0000000000000042.

PMID:
24185383
19.

[Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].

Yuan GW, Wu LY, Yao HW, Hou JL, Li XG, Liu LY.

Zhonghua Zhong Liu Za Zhi. 2009 Sep;31(9):710-3. Chinese.

PMID:
20021871
20.

Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.

Safra T, Berman T, Yachnin A, Bruchim I, Meirovitz M, Barak F, Atlas I, Levy T, Rosengarten OS.

Int J Gynecol Cancer. 2013 Mar;23(3):475-80. doi: 10.1097/IGC.0b013e3182866944.

PMID:
23435437

Supplemental Content

Support Center